SMAD specific E3 ubiquitin protein ligase 2Genealiases: []
Q-omics provides the consensus-scored SMURF2 profile across patient tissues and cancer cell-line models. SMURF2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SMURF2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SMURF2 protein abundance shows 22,944 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, HNSC, and LUAD as cancer lineages where SMURF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMURF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMURF2 survival associations across molecular data types. SMURF2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMURF2 RNA expression–survival associations across cancer types. High SMURF2 expression shows unfavorable associations in MESO, ACC and HNSC, but favorable associations in KIRC, LAML and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SMURF2 RNA expression.
This table summarizes SMURF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SMURF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMURF2 shows lower tumor expression in KICH and LUSC and higher tumor expression in HNSC, LIHC, CHOL and COAD. The HNSC box plot shows higher SMURF2 RNA expression in tumor versus normal tissue (log2 FC = +1.275, t-test p < 0.001).
This table shows molecular features associated with SMURF2 in patient tissues and cancer cell lines. In patient samples, SMURF2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SMURF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
